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Abstract
Background: Antibiotic-induced disturbances of the human microbiota have been implicated in the development
of chronic autoimmune conditions. This study aimed to assess whether antibiotic use is associated with the onset
of rheumatoid arthritis (RA).
Methods: A nested case-control study was conducted utilising data from the primary care Clinical Practice
Research Datalink (CPRD). Patients with an incident diagnosis of RA were identified (1995–2017). Each case was
matched on age, gender, and general practice to ≥ 5 controls without RA. Conditional logistic regression was used
to examine previous antibiotic prescriptions and RA onset after controlling for confounding factors.
Results: We identified 22,677 cases of RA, matched to 90,013 controls, with a median follow-up of 10 years before
RA diagnosis. The odds of developing RA were 60% higher in those exposed to antibiotics than in those not
exposed (OR 1.60; 95% CI 1.51–1.68). A dose- or frequency-dependent association was observed between the
number of previous antibiotic prescriptions and RA. All classes of antibiotics were associated with higher odds of
RA, with bactericidal antibiotics carrying higher risk than bacteriostatic (45% vs. 31%). Those with antibiotic-treated
upper respiratory tract (URT) infections were more likely to be RA cases. However, this was not observed for URT
infections not treated with antibiotics. Antifungal (OR = 1.27; 95% CI 1.20–1.35) and antiviral (OR = 1.19; 95% CI 1.14–
1.24) prescriptions were also associated with increased odds of RA.
Conclusion: Antibiotic prescriptions are associated with a higher risk of RA. This may be due to microbiota
disturbances or underlying infections driving risk. Further research is needed to explore these mechanisms.
Background
Antibiotics are prescribed to treat a wide range of bacterial
infections including respiratory, gastrointestinal (GI), and
urinary tract infections. In the UK, around 30% of all pa-
tients registered in primary care receive at least one anti-
biotic prescription per year [1]. As well as targeting
bacterial pathogens, antibiotics can also disturb the gut
microbiota. This highly diverse and dynamic microbial eco-
system plays an integral part in human health, modulating
host metabolism and immunity [2–4]. Importantly, the
microbiota can be influenced by numerous factors, with
antibiotic treatment suggested as among the most
significant [5]. Antibiotic treatment can significantly disturb
the gut, oral, and skin microbiota, leading to an immediate
reduction in microbial abundance and species diversity.
There is a significant body of data indicating that antibiotic
usage, particularly during childhood, is a major risk factor
for increasing susceptibility to infections and development
of atopy and inflammatory bowel diseases (ulcerative col-
itis, Crohn’s disease) [6]. More recently, studies indicate
antibiotic usage appears to increase the risk of autoimmune
conditions, including type 1 diabetes, autoimmune liver
disease, and juvenile idiopathic arthritis (JIA) [7–10].
RA is a chronic autoimmune inflammatory disease,
which is characterised by autoimmune antibody produc-
tion, which directly leads to bone joint destruction, and
associated RA pathology. One of the autoantibodies as-
sociated with RA (antibodies to citrullinated peptide
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antigens (ACPA)) is produced in response to bacterial
components that closely mimic host cell receptors, e.g.
Porphyromonas gingivalis and Aggregatibacter actinomy-
cetemcomitans [11, 12]. Indeed, prior infections, and gin-
givitis in particular, have been identified as potential risk
factors for RA development [13]. Notably, gingivitis is a
very common oral infectious disease in the UK popula-
tion, with most adults having some form of gum disease
[14]. However, the proportion of this population who de-
velop RA is extremely low, suggesting other aetiological
factors are at play. Several experimental studies have
linked the microbiota to the development of inflamma-
tory arthritis. Germ-free mouse models do not develop
inflammatory arthritis, and certain bacteria (e.g. seg-
mented filamentous bacteria, a mouse-specific taxa) have
been shown to induce inflammatory TH17 responses,
which may drive associated immune-mediated pathology
and joint destruction [15, 16]. In humans, previous stud-
ies have indicated that there are differences in micro-
biota composition between healthy and disease cohorts.
Although RA microbiota profiles reported have varied
between different countries [17, 18], all studies have in-
dicated reduced microbial diversity, which may be asso-
ciated with external factors such as antibiotic usage.
Thus, the aim of this study was to investigate the associ-
ation between antibiotic prescriptions and the onset of
RA using a large, UK-based, primary care dataset.
Methods
Data source and study population
We used the Clinical Practice Research Datalink (CPRD), a
large database containing UK primary care medical records
of anonymised patients. This includes coded symptoms,
diagnoses, test results, referrals, and prescriptions. CPRD
covers more than 7% of the UK population and is a repre-
sentative of the general UK population in terms of age and
sex [19]. Practices contributing data to the CPRD receive
training on recording information, and the database is sub-
jected to quality checks. Data are only used when a practice
has reached a certain standard of quality. This is defined as
being up to standard (UTS). Prescriptions, test results, and
referrals are recorded automatically when requested by the
treating clinician. It can be expected that all reasons for
consultation of any significance are also recorded.
We identified individuals with a first-ever recorded diag-
nosis of RA between 1990 and 2017. Diagnosis of RA was
ascertained by Read Codes, which have been previously
shown to be accurate with a high positive predictive value
[20, 21]. Each RA case was assigned an index date corre-
sponding to the incident diagnosis date and individually
matched to up to five controls on the year of birth, gender,
and general practice. Those with less than 5 years of fol-
low-up before the index date were excluded.
Antibiotic prescriptions
In UK primary care, all prescriptions are recorded auto-
matically when issued by the clinician, including a code
for the chapter of the British National Formulary (BNF)
under which they were issued. Therefore, all primary
care prescriptions appear in the CPRD. All antibiotic
prescriptions recorded more than 1 year before the
index date were identified using relevant British National
Formulary (BNF) chapter headings. We only focused on
systemic oral antibiotics, excluding topical antibiotics.
Individuals were considered exposed if they received one
or more antibiotic prescriptions more than a year before
the index date. Antibiotics prescribed in the year before
the RA diagnosis were not considered, as they may be
prescribed for early RA symptoms.
Covariates
For cases and controls, we extracted information on body
mass index (BMI), alcohol consumption, and smoking sta-
tus (current or ex-smoker/never smoker) using the latest
measure before the index date. BMI was categorised into
four categories: underweight (BMI < 18.5), normal (18.5–
24.9), overweight (25–29.9), and obese (≥ 30). Charlson
index was used to quantify comorbidities before the index
date. Finally, we extracted information on commonly oc-
curring infections (upper and lower respiratory tract, urin-
ary tract, GI) before the index date.
Code lists used to define exposures, outcome, and co-
variates are available from keele.ac.uk/mrr.
Statistics analysis
Characteristics of the cases and controls were summarised
using descriptive statistics (frequencies and percentages).
We used conditional logistic regression to assess the asso-
ciation between antibiotic exposure and the risk of incident
RA. We adjusted our estimates for a wide range of con-
founding factors using a multivariable regression model.
Missing information on BMI was considered as a separate
category and included in the analysis. Recency of antibiotic
use was assessed as the time between antibiotic therapy
end date and the occurrence of RA. Using similar methods,
we assessed the impact of antibiotic type (bacteriostatic/
bactericidal; Additional file 1: Table S1) on RA onset.
To explore whether the underlying infection, rather than
the antibiotic prescription, is associated with increased risk
of RA (confounding by indication), the strength of associ-
ation between previous infections and RA was assessed
and stratified by infection types. Frequency-dependent as-
sociations (number of previous infections) with RA were
also explored. For this purpose, similar infections recorded
less than 30 days apart were considered as a single episode.
As upper respiratory tract (URT) infections may or may
not warrant antibiotic therapy, we stratified our analysis by
treatment modality (antibiotic-treated URT or untreated
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URT). Treated URT was defined as those prescribed any
antibiotics within 30 days of their initial infection code. For
each patient, we counted the number of antibiotic-treated
and untreated URT infections before the index date and
assessed the association with RA. For comparison, we
assessed the association between non-bacterial anti-
microbial agents (anti-fungal and anti-viral) and the
risk of RA.
It may be possible that certain early RA symptoms
may have triggered antibiotic therapy (protopathic bias).
To account for this bias, we repeated our primary ana-
lysis after redefining our index date based on patients’
first referrals to rheumatology clinics within 5 years be-
fore their recorded RA diagnosis (similar date was im-
posed on matched controls). All statistical analysis was
conducted using Stata version 14.
Approvals
This study was approved by the CPRD’s Independent
Scientific Advisory Committee (ISAC) reference number:
18_245.
Results
Participant characteristics
Twenty-two thousand six hundred seventy-seven cases of
incident RA cases were individually matched to 90,013 con-
trols. Baseline characteristics of the study population are
summarised in Table 1. Compared to controls, a larger pro-
portion of RA cases were obese (BMI > 30; 27% vs. 32%),
were more likely to smoke (18% vs. 21%), and had a higher
number of comorbidities (no comorbidities 63% vs. 57%).
Antibiotics and RA
RA cases received more antibiotic prescriptions than con-
trols, but over 80% in each group had received a prescrip-
tion in the 10 years before the index date (Table 2).
Penicillins were the most commonly prescribed antibiotics
(72% of participants received at least one prescription be-
fore index data), followed by macrolides (33%), trimetho-
prim (31%), cephalosporins (25%), and tetracyclines and
quinolones (both 13%). After adjusting for potential con-
founding factors, the odds of having been exposed to anti-
biotics were significantly higher in RA cases than in
controls (OR 1.60; 95% CI 1.51–1.68). Redefining our
index date based on the first referral to the rheumatology
did not change our overall finding (adjusted OR = 1.68;
95% CI 1.59–1.76). A frequency-dependent relationship
was observed between the number of prescriptions and
the odds of RA. The magnitude of association with RA in-
creased with an increasing number of unique antibiotic
prescriptions. The timing of antibiotic exposure was im-
portant, with higher odds of RA in those last exposed to
antibiotics in 1 to 2 years before the index date (OR 1.80;
95% CI 1.70–1.90) than in those last exposed between 5
and 10 years before the index date (OR = 1.57; 95% CI
1.49–1.66).
All classes of antibiotics were associated with higher
odds of RA, with clindamycin having the highest odds
ratio (Fig. 1). Based on the mode-of-action, the odds of
RA were 45% higher in those prescribed antibiotics in-
ducing a bactericidal response (i.e. lyse bacteria) (OR =
1.45; 95% CI 1.39–1.51) compared to those not pre-
scribed antibiotics. The increase in odds was slightly
lower with antibiotics inhibiting bacteria (i.e. bacterio-
static) when similar comparisons were made (OR = 1.31;
95% CI 1.27–1.36).
RA and infection
Cases were more likely to have a record of infection be-
fore their RA diagnosis (Table 3). This increased odds of
RA among those with a previous history of infection
ranged between 7% (urinary tract infection; OR = 1.07;
95% CI 1.02–1.12) and 37% (for LRT infections; OR =
1.37; 95% CI 1.32–1.41). A frequency-dependent associ-
ation also existed between the number of previous infec-
tions and the odds of RA. More than 87% of lower
respiratory and urinary tract infections were treated with
antibiotics within 30 days. This proportion was lower for
URT (74%) and GI infections (21%). Those with anti-
biotic-treated URT infections were more likely to be RA
cases. However, the association was not observed for the
number of untreated URT infections.
Additional analysis
A total of 1580 (7%) and 3166 (14%) of RA cases re-
ceived at least one antiviral and antifungal prescription,
respectively, before the index date. After adjusting for
confounding factors, including antibiotic use, both anti-
fungal (OR = 1.19; 95% CI 1.14–1.24) and antiviral drugs
(OR = 1.27; 95% CI 1.20–1.35) were associated with in-
creased risk of RA.
Discussion
Using routinely collected primary care data, we have
assessed the association between antibiotic use and RA
onset. Those exposed to one or more antibiotic prescrip-
tions were 60% more likely to develop RA than their un-
exposed counterparts. A frequency-dependent association
was observed between previous antibiotic prescriptions
and RA, and the odds of RA were higher in those with
more recent antibiotic exposure. The odds of RA varied
by class and mode-of-action of antibiotics. Infection type
was also important; those with antibiotic-treated URT in-
fections were more likely to be RA cases. However, the
same association was not observed for the number of un-
treated URT infections. Finally, other anti-microbial
agents (i.e. antifungals and antivirals) were associated with
increased RA risk.
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Respiratory infections showed the strongest associ-
ation with RA. Chlamydia pneumoniae, Streptococcus
pyogenes, Streptococcus pneumoniae, and Klebsiella
pneumoniae are often associated with respiratory tract
infections, and previous studies have linked specific
pathogens (e.g. C. pneumoniae) with increased levels of
circulating autoimmune antibodies that may play a role
in RA pathology [22]. However, as numerous pathogens
are associated with URT infections, other factors may
also play a strong role in disease association. Indeed, our
analysis indicates the strongest association is only
present in antibiotic-treated cases of URTs (74% patients
treated within 30 days of diagnosis), not untreated URT
infections, suggesting that associated antibiotic usage is
likely to be the main associative factor for the increased
incidence of RA in this cohort. A previous case-control
study in JIA also suggested that antibiotic-treated URT
infections were more strongly associated with JIA than
untreated URT infections [8]. It should be noted that
antibiotic-treated respiratory infections may be expected
Table 1 Basic characteristics of cases and controls
Variable Controls (n = 90,013) RA cases (n = 22,677)
N % N %
Year of RA diagnosis
1995–1999 8086 9 2033 9
2000–2004 15,253 16.9 3849 17
2005–2009 24,713 27.5 6232 27.5
2010–2014 31,699 35.2 7980 35.2
2015–2017 10,262 11.4 2583 11.4
Age at index (years)
< 40 19,064 21.2 4857 21.4
40–59 20,416 22.7 5095 22.5
60–69 22,257 24.7 5588 24.6
70–79 19,238 21.4 4843 21.4
80–89 8366 9.3 2093 9.2
≥ 90 672 0.7 201 0.9
Mean age (SD) 61.4 (14.1) 61.4 (14.3)
Gender, female 60,620 67.3 15,276 67.4
Median follow-up before RA diagnosis (IQR) 10 (7–14) 10 (7–14)
Body mass index
Underweight 22,337 24.8 5102 22.5
Normal 2402 2.7 694 3.1
Overweight 28,948 32.2 7456 32.9
Obese 24,610 27.3 7308 32.2
Missing 11,716 13 2117 9.3
Smoking status
Never/ex-smokers 74,043 82.3 17,840 78.7
Current 15,970 17.7 4837 21.3
Alcohol
Never/ex-drinker 29,159 32.4 7341 32.4
1–10 units/weeks 46,692 51.9 11,976 52.8
> 10 units/week 14,162 15.7 3360 14.8
Charlson comorbidity index
0 56,683 63 12,813 56.5
1–2 24,356 27.1 7219 31.8
3–5 7937 8.8 2355 10.4
> 5 1037 1.2 290 1.3
Sultan et al. BMC Medicine          (2019) 17:154 Page 4 of 9
to be more severe, thus potentially confounding analysis;
nonetheless, the link between the severity of an infection
and antibiotic prescription practices is not currently
clear. Whilst there is an expectation that this should be
the case, numerous previous studies have highlighted
that clinician-dependent decisions and preference are
the likely driver for an antibiotic prescription for infec-
tions that notably are rarely confirmed by microbio-
logical testing (with many cases potentially being of viral
origin) [23, 24]. Further analysis of antibiotic usage indi-
cates that all classes increase the risk of RA develop-
ment, which suggests that provision of antibiotics rather
Table 2 Association between antibiotic prescriptions and RA
Variables Controls Cases Crude OR (95%
CI)
Adjusted ORa
(95% CI)N % N %
Any antibiotic use
No prescriptions 16,242 18.0 2369 10.4 Reference Reference
≥ 1 prescription 73,771 82.0 20,308 89.6 2.02 (1.92–2.12) 1.60 (1.51–1.68)
No. of prescriptions (quartile) (median (IQR))
1 (1 (1, 2)) 20,321 22.6 4128 18.2 1.49 (1.41–1.57) 1.40 (1.32–1.48)
2 (4 (3, 5)) 18,923 21.0 4592 20.2 1.85 (1.75–1.96) 1.66 (1.57–1.77)
3 (8 (7, 9)) 17,524 19.5 5231 23.1 2.36 (2.23–2.50) 2.04 (1.92–2.17)
4 (19 (14, 29)) 17,003 18.9 6357 28.0 3.10 (2.93–3.28) 2.56 (2.39–2.74)
Recency of therapy (therapy termination)b
1–2 years before diagnosis 30,041 35.2 9557 43.9 2.34 (2.23–2.46) 1.80 (1.70–1.90)
2–5 years before diagnosis 26,898 31.5 7016 32.2 1.91 (1.81–2.01) 1.57 (1.49–1.66)
5–10 years before diagnosis 12,183 14.3 2846 13.1 1.70 (1.59–1.80) 1.48 (1.39–1.58)
Antibiotic type
Bacteriostatic
Unexposedc 43,580 48.4 8778 38.7 Reference Reference
Exposed 46,433 51.6 13,899 61.3 1.55 (1.50–1.60) 1.31 (1.27–1.36)
Bactericidal
Unexposedd 21,892 24.3 3595 15.9 Reference Reference
Exposed 68,121 75.7 19,082 84.2 1.80 (1.72–1.87) 1.45 (1.39–1.51)
aAdjusted for age, BMI, smoking status, Charlson comorbidity index, alcohol, and infections
bMost recent course of therapy
cIncluding those people exposed only to bactericidal antibiotics
dIncluding those people exposed only to bacteriostatic antibiotics
Fig. 1 Association between RA and antibiotic class. Comparison of individual antibiotic classes with no antibiotics. Estimates are adjusted for
Charlson index, age category, BMI category, smoking, alcohol consumption, and infection types
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than type/class is associated with RA. The odds ratio for
clindamycin was the largest, which was also observed by
Arvonen et al. [10] in JIA patients. However, the confidence
interval is very wide, which reflects the small numbers of
people prescribed with this antibiotic (n = 307, 0.27% of the
sample); thus, this medication is not expected to have a
strong influence on the overall association of antibiotic pre-
scription with RA diagnosis. Breaking down antibiotics into
their mode-of-action revealed that there was a stronger as-
sociation of bactericidals than bacteriostatics with RA (OR
1.45 vs. 1.31), which may correlate with increased gut
microbiota disturbances and link to our observation that
antibiotic exposure up to 10 years prior to diagnosis was as-
sociated with increased risk of RA [5]. Lysis of bacteria by
bactericidal antibiotics may also be associated with further
microbial compounds circulating systemically and inducing
autoimmune antibodies that are associated with RA path-
ology. However, it is currently unclear if the major driver is
infection and/or antibiotic usage; therefore, these observa-
tions require extensive additional studies (both case-con-
trolled and mechanistic) to determine direct causation.
The rise in inflammatory, allergic, and autoimmune
conditions over the past 20–30 years has been linked to
improved diagnostics and a more ‘Western’ lifestyle,
which includes the widespread use of antibiotics [9]. Im-
portantly, these antibiotics, whilst crucial in treating ser-
ious bacterial pathogens, also affect beneficial microbiota
members, leading to a reduction in microbial diversity. In
some cases, these disturbances appear to be longer term,
whilst in others, the microbiota appears to revert to base-
line [25, 26]. However, even short-term changes may inter-
rupt the key immune pathways, which may manifest as
symptoms in later-life conditions. Indeed, there is now
strong evidence linking antibiotic-induced microbiota dis-
turbances to numerous pathologies. Indeed, IBD is defined
as ‘a chronic intestinal inflammation that results from
host-microbial interactions in a genetically susceptible in-
dividual’, and previous studies have indicated a sevenfold
higher risk of IBD development in response to antibiotic
use [27]. Furthermore, many mechanistic preclinical stud-
ies have provided strong evidence that an antibiotic-dis-
turbed gut microbiota plays a direct role in disease
Table 3 Association between the history of infections and RA
Variables Controls Cases OR (95% CI) Adjusted OR*
(95% CI)N % N %
Infection ever before diagnosis
Lower respiratory tract 31,400 34.9 10,050 44.3 1.56 (1.51–1.61) 1.37 (1.32–1.41)
Upper respiratory tract 41,786 46.4 12,258 54.1 1.42 (1.38–1.47) 1.26 (1.22–1.31)
Gastrointestinal 8352 9.3 2699 11.9 1.33 (1.27–1.40) 1.19 (1.13–1.25)
Urinary tract 11,037 12.3 3179 14 1.19 (1.13–1.24) 1.07 (1.02–1.12)
Infection episodes
0 34,899 38.8 6835 30.1 Reference Reference
1 18,503 20.6 4366 19.3 1.26 (1.21–1.32) 1.22 (1.72–1.28)
2 11,041 12.3 2990 13.2 1.48 (1.41–1.56) 1.42 (1.35–1.49)
3 7091 7.9 2066 9.1 1.63 (1.54–1.73) 1.54 (1.46–1.64)
≥ 4 18,479 20.5 6420 28.3 2.02 (1.93–2.11) 1.86 (1.78–1.94)
No. of treated URT
0 8466 20.3 2078 17.0 Reference Reference
1 16,536 39.6 4510 36.8 1.11 (1.05–1.18) 1.10 (1.04–1.17)
2 7052 16.9 2236 18.2 1.29 (1.21–1.38) 1.27 (1.19–1.50)
3 3554 8.5 1233 10.1 1.41 (1.30–1.53) 1.39 (1.28–1.51)
≥ 4 6178 14.8 2201 18.0 1.45 (1.36–1.55) 1.42 (1.32–1.52)
No. of untreated URT
0 21,981 52.6 6510 53.1 Reference Reference
1 13,893 33.2 3908 31.9 0.95 (0.91–0.99) 0.95 (0.91–1.00)
2 3714 8.9 1132 9.2 1.03 (0.96–1.11) 1.02 (0.95–1.07)
3 1274 3 385 3.1 1.02 (0.91–1.15) 1.00 (0.89–1.13)
≥ 4 924 2.2 323 2.6 1.18 (1.04–1.34) 1.14 (1.00–1.29)
*Adjusted for age, BMI, smoking status, Charlson comorbidity index, alcohol, and presence/absence of LRT, URT, GII, and UTI
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pathology [28]. Similarly, alongside the genetic susceptibil-
ity component to RA, it is apparent that additional envir-
onmental factors, including microbes, may play a role in
disease onset. Horton et al. performed a case-controlled
study of antibiotic usage and JIA that indicated that any
antibiotic exposure was associated with increased risk of
developing JIA [8]. This association was also the frequency
of antibiotic use-dependent, supporting our findings that
inflammatory arthritis may be associated with antibiotic-
related gut microbiota disturbances. Our study is the first
to investigate the association between antibiotic usage and
RA and suggests that antibiotics may be a major risk fac-
tor for RA development.
Small scale studies profiling the microbiota of RA
patients have indicated reduced bacterial taxon diversity.
A study from the mid-1990s focussing on microbial-de-
rived compounds, i.e. cellular fatty acids, indicated a dif-
ference between RA patients and controls, suggesting a
microbiota component to RA pathology [29]. Other
studies using 16S rRNA microbiota analysis have indi-
cated changes in different bacterial genus ranging from
reductions in Bacteroides, Prevotella, and Porphyromo-
nas to another study indicating that a subpopulation of
early RA patients had increased prevalence of Prevotella
copri; however, it should be noted that these observed
microbiome changes may also be a result of RA disease
state [30, 31]. Using more sensitive microbiota profiling
approaches, i.e. shotgun metagenomics (involves sequen-
cing the entire gene content of microbiota samples),
Zhang et al. determined that both oral and gut microbial
communities are altered in RA patients, with Bifidobacter-
ium bifidum and Haemophilus spp. reduced and nega-
tively correlated with the levels of serum autoantibodies,
whereas Lactobacillus salivarius was over-represented,
particularly in patients with very active RA [17]. A lung
microbiota study, using metataxonomic 16S rRNA profil-
ing, indicated that bronchoalveolar lavage fluid (BAL)
from RA patients had reduced species diversity, which
correlated with RA-associated lung pathology, and sug-
gests that lung microbiota changes may also be associated
with clinical outcomes [32]. However, all these studies
were carried out in small numbers of patients (< 80), and
none has investigated the association with antibiotic use,
thus highlighting the need for further studies in this area.
Alongside bacteria, the microbiota also includes fungi
and viruses, and more recent studies have indicated that
these microorganisms play a key role in microbial
ecosystem structuring and modulating host immune re-
sponses [33, 34]. Thus, our findings that increased risk
of RA was also observed for patients prescribed other
anti-microbial agents (i.e. antifungals, antivirals), albeit a
lower risk than antibiotics, suggests that the risk may be
in part driven by disturbances in these microbial groups,
which warrants further exploration. Additional analysis
to assess the potential confounding effect of antifungals
and antivirals (data not shown) suggested that prescrip-
tions of the classes of medication were independent of
each other.
Our study has a number of limitations. First, there
may be misclassification of RA cases, as we were reliant
on general practitioners accurately record RA diagnosis.
However, previous studies have shown high accuracy of
RA recording in primary care; therefore, the risk of mis-
classification will be minimal [20, 21]. On that note, we
considered incident RA cases based on the earliest re-
cording of RA in the patients’ primary care record. This
may sometimes not reflect the true date of RA onset as
it should be diagnosed by a specialist rheumatologist.
Any delay in the recording of RA in primary care data
may lead to protopathic bias. However, our finding
remained unchanged when we conducted a sensitivity
analysis after redefining our index date based on the first
referral to a rheumatologist. Second, factors such as par-
ity and breastfeeding are associated with increased risk
of RA, which may have confounded our observed associ-
ation. However, the impact of this confounding will be
limited, as the onset of RA is relatively rare in the youn-
ger population. Third, we may have underestimated the
proportion of individuals exposed to antibiotics, as we
did not have information on antibiotics prescribed in
secondary care. Given that we found that patients with
RA have more comorbidities compared to controls, it is
reasonable to assume that RA cases may have had more
hospital admissions and subsequently received more sec-
ondary care prescriptions. Thus, we may have underesti-
mated the association between antibiotic prescriptions
and RA. In addition, there may be confounding by the
underlying infection. Whilst increased risk of RA was
not observed for those with URT infections not treated
with antibiotics, this finding should be interpreted with
caution as antibiotics may be a marker of infection se-
verity (albeit with the caveats highlighted above). Finally,
we did not determine relative doses of antibiotics taken;
therefore, we used frequency of prescriptions to correl-
ate with potential dose and other commonly prescribed
drugs, e.g. proton pump inhibitors may be correlated
with antibiotic use and in turn confound the observed
influence on RA risk (and the microbiota), with add-
itional studies required to explore these complex issues
[35]. This finding cannot be generalised to other infec-
tions as we have shown that the risk of RA varies by the
infection site.
Although we have identified a strong association be-
tween antibiotic usage and the onset of RA, there remain
many unanswered questions, particularly whether this is
related to infections themselves, alterations in the micro-
biota, or a combination of the two. Further clinical infor-
mation on the causative pathogens, and their association
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with the risk of RA, may shed light on this, and further
larger microbiota profiling studies, using cutting edge se-
quencing approaches, may provide a further resolution on
the microbes present or absent and links to specific mi-
crobial components. However, these studies should also
be underpinned by mechanistic investigations that help
researchers define what processes are involved, providing
an important platform for the development of new pre-
vention or intervention strategies. Indeed, with the identi-
fication of microbiota disturbances in several human
disease pathologies, modulation of the microbiota has be-
come a target for intervention and treatment. This may
also prove to be useful in the context of RA, although 80%
of people had a recorded prescription for an antibiotic,
the odds of having received an antibiotic were 60% higher
in those with RA. To date, there have been a limited num-
ber of randomised clinical trials using probiotics (live or-
ganisms which, when administered in adequate amounts,
confer a health benefit on the host), to treat RA, and out-
comes have been inconsistent [36]. However, immune
readouts indicate a reduction in inflammatory cytokines
(TNF-α and IL-8) and a concurrent increase in IL-10 (an
anti-inflammatory cytokine) [37]. We feel this is an im-
portant study to highlight other aetiological factors, such
as antibiotics, that may contribute to RA risk. Studies of
this nature, profiling a huge longitudinal population base,
are critical for next stage detailed clinical studies and de-
velopment of innovative therapies for this debilitating
disease, including probing underlying mechanisms and
potential associations between microbiota disturbances,
infection, and RA onset.
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